eXoZymes Inc., a leader in AI-engineered enzyme technology, has announced a breakthrough in biomanufacturing with their spinout NCTx. The company successfully achieved lab-scale validation, producing 4 grams of N-trans-caffeoyltyramine $(NCT)$ with over 99% purity and a 96% yield. This milestone highlights the potential of eXoZymes' AI-driven platform to transform sustainable feedstocks into essential chemicals. The results demonstrate significant advancements in synthetic biology, with rapid development from concept to production in just five months and at a reduced cost. eXoZymes is actively seeking additional partners to further accelerate the commercialization of NCT, which is recognized as safe for functional foods and has potential applications in prebiotics, dietary supplements, and pharmaceuticals. The results have already been presented, showcasing the innovation in sustainable and efficient biomanufacturing.